Tempus, a prominent player in the realm of artificial intelligence and precision medicine, has unveiled a strategic and multi-year research collaboration with Bristol Myers Squibb.
Together, these two entities are set to embark on a journey aimed at identifying and validating new targets swiftly and with heightened confidence. This process will leverage multimodal datasets, computational methodologies, and patient-derived disease models, particularly in the realm of specific cancer disease areas.
The collaborative efforts of the Tempus and Bristol Myers Squibb teams will initially be concentrated on the crucial task of pinpointing fresh drug targets.
The primary objective is to broaden the spectrum of options for patients who lack effective therapies or have become refractory to existing treatments. This joint endeavor will unfold in a highly collaborative manner, with both teams delving into Tempus' expansive multimodal database to analyze disease cohorts.
Employing systems biology approaches, they aim to unearth novel targets that can be rapidly and iteratively tested using Tempus' repository of patient-derived organoids.
Tempus, recognized as a technology powerhouse, is at the forefront of advancing precision medicine through the practical application of artificial intelligence in the healthcare domain.
Boasting one of the world's largest libraries of multimodal data and an operating system that renders this data accessible and practical, Tempus delivers AI-enabled precision medicine solutions to physicians. This not only facilitates personalized patient care but also catalyzes the discovery, development, and delivery of optimal therapeutics.
The overarching goal is to ensure that each patient reaps the benefits of treatments informed by the experiences of those who came before them.
Tempus achieves this by furnishing physicians with tools that evolve and learn as the company accumulates more data, thereby contributing to a continuous cycle of improvement and innovation in healthcare.
